The real retatrutide before and after is a measured one: 24.2% mean body-weight loss at 48 weeks on 12 mg, against 2.1% on placebo. The photos you'll find are impossible to verify. A photo shows one person at two moments, and it can't tell you how likely that result was.
The short answer. Retatrutide: At 48 weeks the 12 mg arm averaged a 24.2% reduction in body weight.
- Placebo in the same trial averaged 2.1%, the comparison a photograph never includes.
- 83% of participants in that arm lost at least 15% of their body weight.
- That leaves a minority who did not reach the threshold, and the spread matters as much as the mean.
The honest retatrutide before-and-after is a dataset, not a photograph. Look at 48 weeks. The 12 mg arm averaged a 24.2% drop in body weight. Placebo averaged 2.1%. In that arm, 83% lost at least 15% of body weight. That spread tells you more than any image pair. It includes the people at the bottom of it.
Week by week: what the trial actually measured
Jastreboff and colleagues randomized 338 adults with obesity. The design used five retatrutide arms and placebo. Dosing ran once weekly for 48 weeks. Laid out on a timeline, this is what was measured, when, and in which arm. It is the closest thing to a before-and-after that exists for this compound. It reports every participant, not just the photogenic ones.
| Week | Trial arm | Mean body-weight change | What the trial recorded at that point |
|---|---|---|---|
| Week 0 | All six arms | Baseline | 338 adults with obesity randomized across five retatrutide arms and placebo, dosed once weekly |
| Weeks 1–12 | The five retatrutide arms | No separate mean published for this window | Dose escalation. Roughly the first quarter of the trial was spent titrating up to target dose rather than sitting at it |
| Week 48 | Placebo | −2.1% | The comparison a photograph never includes |
| Week 48 | 1 mg | −8.7% | −6.6 points versus placebo |
| Week 48 | 4 mg | −17.1% | −15.0 points versus placebo |
| Week 48 | 8 mg | −22.8% | −20.7 points versus placebo |
| Week 48 | 12 mg | −24.2% | −22.1 points versus placebo. In this arm 100% of participants lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15% |
| After week 48 | — | Not measured | The trial ended at 48 weeks with the weight curve still falling. No published trial has run to 72 or 96 weeks |
At time of publication, that 24.2% was a record. No pharmaceutical agent had documented a larger mean body-weight reduction. It sits closer to bariatric-surgery territory than to anything else in a pill or a syringe.
Why the photographs can’t report that
Before-and-after imagery is the worst evidence in this category. It is also the most abundant. There is no baseline control. Nobody verifies that the person took what they say they took. Nobody verifies the dose they claim either.
There is also no way to separate the drug from everything else that changed. And selection pressure runs heavily toward the people it worked best for. Nobody posts the photo where nothing happened.
Trial data does something the photos structurally can't. It reports the whole distribution, including the tail.
The part photos never show: the spread
Threshold-response data is where individual variation becomes visible. On the 12 mg arm:
- 100% of participants lost at least 5% of body weight (versus 27% on placebo)
- 93% lost at least 10% (versus 9%)
- 83% lost at least 15% (versus 2%)
Two readings of that are both correct. It's a remarkably consistent response, because nearly everyone in the top-dose arm lost clinically meaningful weight. It's also still a distribution: roughly one in six people on the highest dose didn't reach 15%.
A before-and-after photo is a single draw from that distribution, chosen by someone with a reason to pick the best one.
A photograph reports one draw from the distribution. The trial reports the distribution, including the sixth person who didn’t reach 15%.
— WTBP Research Team note, 2026
Expect the Phase 3 number to be lower. Phase 2 trials over-report efficacy relative to Phase 3 as a matter of structure, not fraud. Smaller samples, more adherence support at sites, and selection effects that favor responders all push the same way.
We'd expect TRIUMPH to regress into the 18–22% range. That would still be the best result in the class. It just wouldn't be 24.2%.
What the timeline looked like
Participants titrated to target dose over roughly the first 12 weeks. So the first quarter of the trial was spent getting to the dose rather than sitting at it.
The weight curve through 48 weeks hadn't plateaued when the study ended. Nobody knows where it goes at 72 or 96 weeks, because no published trial has run that long. Our dosing protocol page covers how the escalation was structured.
The question the photos definitely don't answer
What happens when you stop. No published retatrutide withdrawal trial exists, but the class has an answer and it isn't encouraging.
Tirzepatide's SURMOUNT-4 maintenance trial found that discontinuation produced major weight regain. That's what reframed the drug as chronic therapy rather than a course of treatment, and we can't see a mechanistic reason retatrutide would behave differently.
A before-and-after pair captures a moment inside a treatment period. It tells you nothing about the year after it.
For how retatrutide's numbers sit against the rest of the class, see retatrutide vs tirzepatide and the 2026 GLP-1 class comparison.
Frequently asked questions
What weight loss did retatrutide produce in the trial?
At 48 weeks, mean body-weight reduction was 24.2% on the 12 mg dose, 22.8% at 8 mg, 17.1% at 4 mg and 8.7% at 1 mg, against 2.1% on placebo. On the 12 mg dose, 83% of participants lost at least 15% of body weight.
How long does retatrutide take to work?
The trial ran 48 weeks and the weight curve had not plateaued at the end of it. Participants also spent the first ~12 weeks titrating up to target dose, so the steepest part of the response came after that window rather than in the first month.
Are retatrutide before-and-after photos reliable?
Photographs are the least reliable evidence in this category. There's no baseline control, no verification the person took what they claim, and heavy selection for the best responders. The trial's threshold-response data tells you far more, because it reports what share of participants hit each weight-loss threshold, including the ones who did poorly.
Does the weight come back if you stop?
In tirzepatide's SURMOUNT-4 maintenance trial, discontinuation produced major weight regain, which reframed that drug as chronic therapy rather than a course. No equivalent retatrutide withdrawal trial has been published, and we can't see a mechanistic reason it would behave differently.
What we’re watching
TRIUMPH is the readout that matters. It's the Phase 3 program, and it will report a mean weight change in a larger, less hand-held population than the Phase 2 trial did.
We're also watching for a maintenance arm. Until somebody runs a retatrutide withdrawal trial, the regain question is answered by borrowing tirzepatide's data, and that's a borrowed answer rather than a measured one.
What to know now
- At 48 weeks the 12 mg arm averaged a 24.2% reduction in body weight.
- Placebo in the same trial averaged 2.1%, the comparison a photograph never includes.
- 83% of participants in that arm lost at least 15% of their body weight.
- That leaves a minority who did not reach the threshold, and the spread matters as much as the mean.
- The distribution, including the people at the bottom of it, is more informative than any pair of images.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about Retatrutide deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
Self-reports converge on large, fast weight loss. r/Retatrutide had 165,444 members when this was checked. In the four threads verified here, posters report losing 7 kg in 7 weeks, 80 lbs in 6 months, and 93 lbs in about 13 months. The same threads report insomnia, a raised resting heart rate, and disappointment at body composition once the weight is gone. None of it is controlled. No poster reports testing what was in the vial. Two of the four name diet or training changes running alongside. Treat it as uncontrolled self-report, not evidence.
Where the community and the published record disagree. The trials and the community disagree about what goes wrong. A June 2026 medRxiv preprint by Sehgal and colleagues classified 13,589 self-reported retatrutide users and mapped symptoms for 7,823 of them. Its authors write that phase 2 trial findings were dominated by gastrointestinal events and that the Reddit reports were not. The most common Reddit complaints were increased appetite, fatigue, increased energy, nausea, food craving, insomnia, and elevated heart rate. Nausea appears, but it does not lead. The one discontinuation post verified here matches the preprint rather than the trial. u/NJD_77 had reflux early and managed it with antacids he had taken for years. What ended his run was sleep and heart rate. Why the two sets diverge is not settled here. The obvious candidates are that the two groups are not taking the same amounts, and that a trial's fixed adverse-event checklist and an open forum post do not collect the same symptoms. Neither can be tested from this data, and the preprint's own authors call their findings hypothesis-generating. The second contradiction runs the other way, and is more flattering to the community. A widely upvoted post in the sub, 517 points across 275 comments, corrects other users by pointing out that the published phase 2 studies included a 1 mg weekly cohort, which the sub's own folklore had gotten wrong. It links the NEJM and Nature papers by URL.
“That’s right, there was a cohort in the studies who started at, and never exceeded, a 1mg per week dose.”
Busting the biggest myth on this sub - 2mg per week is the lowest dose studied in trials
“I wish I could stick on Reta but I just couldn't handle the insomnia and it was only getting worse not better.”
Had to give up, sadly it's not for me, the sides were intolerable
“Unlike phase 2 trial findings dominated by gastrointestinal events, Reddit reports most often described appetite increase, fatigue, increased energy, nausea, food craving, insomnia, and elevated heart rate.”
Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide
“Down 80lbs in 6 months, healthiest I've been in 6+ years. Just kind of disappointed in the composition of my body now.”
“I started at 227 lbs and I’m currently down to 134 lbs.”
“In this Retatrutide review, I'm sharing my final weight loss results after 6 months”
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y
Threshold-response percentages are from the Phase 2 publication. The weight-regain finding is from tirzepatide's SURMOUNT-4 maintenance trial — no equivalent retatrutide withdrawal trial has reported.